Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR149744C for conversion of atrial fibrillation/flutter
2005-000823-40Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celivarone in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms), sponsored by Sanofi. Primary endpoint: Conversion to sinus rhythm at planned electrical cardioversion. Started Jun 2005; status: completed.
02
Drugs
celivarone
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2005-000823-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000823-40.